FDA Gives Priority Review to Enzalutamide in Non-Metastatic HSPC

News
Article

The FDA sets a Prescription Drug User Fee Act date in the fourth quarter of 2023 for its decision regarding enzalutamide as a treatment for those with non-metastatic hormone-sensitive prostate cancer with a high-risk of biochemical recurrence.

Supporting data for the sNDA came from the phase 3 EMBARK trial (NCT02319837), in which enzalutamide in combination with leuprolide significantly reduced the risk of recurrence or death by 58% compared with placebo plus leuprolide.

Supporting data for the sNDA came from the phase 3 EMBARK trial (NCT02319837), in which enzalutamide in combination with leuprolide significantly reduced the risk of recurrence or death by 58% compared with placebo plus leuprolide.

The FDA has granted priority review to a supplemental new drug application (sNDA) for enzalutamide (Xtandi) for the treatment of non-metastatic hormone-sensitive prostate cancer (HSPC) at high-risk of biochemical recurrence (BCR), according to a press release from Pfizer Inc and Astellas Pharma Inc.1

The regulatory agency set a Prescription Drug User Fee Act date for the fourth quarter of 2023 for enzalutamide in this indication.

Supporting data for the sNDA came from the phase 3 EMBARK trial (NCT02319837), in which enzalutamide in combination with leuprolide significantly reduced the risk of recurrence or death by 58% compared with placebo plus leuprolide (HR, 0.42; 95% CI, 0.30-0.61; P <.0001). In terms of safety, investigators most frequently observed fatigue, hot flush, and arthralgia in those receiving enzalutamide plus leuprolide. The most common adverse effects among patients receiving enzalutamide monotherapy included fatigue, gynecomastia, and arthralgia.

According to data that read out in a plenary session at the 2023 American Urological Association’s Annual Meeting (AUA), treatment with enzalutamide plus leuprolide significantly reduced the progression risk of initiating new antineoplastic therapy by 64% compared with placebo plus leuprolide (HR, 0.36; 95% CI, 0.26-0.49; P <.0001).2 Additionally, investigators noted a 46% reduction in the progression risk of new antineoplastic therapy with enzalutamide alone vs placebo plus leuprolide (HR, 0.54; 95% CI, 0.41-0.71; P <.0001).

Investigators are discussing findings from the EMBARK trial with other regulatory bodies across the world in support of other potential approvals for enzalutamide in this population.

“[BCR] can be one of the first indicators that prostate cancer is returning or will spread, particularly among those patients [who] experience rapid prostate-specific antigen [PSA] doubling times,” Ahsan Arozullah, MD, MPH, senior vice president and head of Oncology Development at Astellas, said in the press release.1 “The addition of [enzalutamide] to leuprolide has shown greater clinical benefit compared [with] placebo plus leuprolide, and we look forward to working with the FDA and other global regulatory authorities to bring [enzalutamide] to these patients.”

Investigators of the double-blind, international EMBARK trial assessed 1068 patients at treatment sites in the United States, Canada, Europe, South America, and the Asia/Pacific region. Patients were randomly assigned to receive 160 mg of enzalutamide once a day plus 22.5 mg of leuprolide every 12 weeks (n = 355), enzalutamide alone (n = 355), or placebo in combination with leuprolide (n = 358).

The study’s primary end point was metastasis-free survival in the enzalutamide plus leuprolide arm vs the placebo plus leuprolide arm. Secondary end points included overall survival, time to castration resistance, time to distant metastasis, time to symptomatic progression, time to clinically relevant pain, and quality of life.

Patients 18 years and older with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, or small cell features were eligible for enrollment on the EMBARK trial. Additional eligibility criteria included having a PSA doubling time of no higher than 9 months and serum testosterone of at least 150 ng/dL.

References

  1. FDA grants priority review for XTANDI® in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence. News release. Pfizer Inc. and Astellas Pharma Inc. August 23, 2023. Accessed August 23, 2023. https://shorturl.at/gjuvW
  2. XTANDI® (enzalutamide) plus leuprolide reduced the risk of metastasis by 58% in non-metastatic hormone-sensitive prostate cancer versus placebo plus leuprolide. News release. Astellas Pharma Inc. April 29, 2023. Accessed August 23, 2023. bit.ly/41SHLjQ
Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content
Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Data Show Short-Course Radiotherapy Increase in Prostate Cancer

November 30th 2023
Article

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.

Docetaxel/SOC Significantly Reduces Mortality in Low PSA Prostate Cancer

November 7th 2023
Article

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

April 26th 2022
Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

With the announcement that the supply of 177Lu vipivotide tetraxetan is now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer.

FDA Classifies 177Lu Vipivotide Tetraxetan Drug Shortage as Resolved

October 31st 2023
Article

With the announcement that the supply of 177Lu vipivotidete traxetanis now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer. 

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC

October 27th 2023
Article

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.